| Oct 31 |
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
|
| Oct 31 |
Bristol-Myers Squibb in charts: Q3 revenue from Eliquis, Opdivo, Yervoy rises, Sprycel falls
|
| Oct 31 |
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
|
| Oct 31 |
Bristol-Myers raises outlook ahead of consensus after Q3 beat
|
| Oct 31 |
Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up
|
| Oct 31 |
Bristol Myers earnings beat expectations, driven by sales of older drugs
|
| Oct 31 |
Bristol Myers: Q3 Earnings Snapshot
|
| Oct 31 |
Bristol-Myers Squibb Company Non-GAAP EPS of $1.80 beats by $0.30, revenue of $11.89B beats by $640M
|
| Oct 31 |
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
|
| Oct 30 |
Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated
|
